Medical Marijuana Inc. (OTCPINK: MJNA) soared 26.23% to $0.385 on a traded volume of 4.68 million shares. The Company pre-announces its fourth quarter earnings. The net income was $3.39 million in the fourth quarter. The gross revenues were $5.10 million, an increase of $4.5 million and over 1,100% from the previous year quarter. The Company provided an update on the expansion of its Red Dice Holdings Dixie Elixirs & Edibles brand nationally and in Colorado through additional market penetration and product development.
Southridge Enterprises Inc. (OTC: SRGE) declined 5.26% to 0.0018. The Company’s subsidiary, Southridge Minerals has issued a corporate update for shareholders of the Company to address questions arising from a recently announced joint partnership with respect to Cinco Minas. Southridge would like to inform shareholders that the joint partnership is no longer valid and the Company is pursuing other joint partnership opportunities at this time. Southridge Minerals focuses on the acquisition, exploration, and development of gold and silver mines in Mexico
Peregrine Pharmaceuticals (NASDAQ: PPHM) moved up 3.77% to $2.20 on a traded volume of 609k shares. Last month, Roth Capital increased the rating of Peregrine Pharmaceuticals from a neutral rating to a buy rating in a research report released. Roth Capital currently has $2.70 price target on the stock. Peregrine Pharmaceuticals is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer.
MediSwipe Inc (OTCQB: MWIP) declined 1.13% to $0.0437 on a traded volume of 2.89 million shares. The 52-week range for the stock is $0.00 and $0.05. The Company has Price/Sales ratio of 258.88. The 50-Day Moving Average and 200-Day Moving Average prices is $0.03 and $0.01 respectively.
AMARANTUS BIOSCI INC (OTCQB: AMBS) increased 3.57% to $0.0870 on a traded volume of 257k shares. The Company has secured an additional $1.4 million of financing commitments through an amendment of the initial Convertible Note with Dominion Capital. The original $600,000 note, dated November 14, 2012, was amended to a face value of $2,000,000 before deducting placement agent fees and other offering expenses. The proceeds will be used to provide funding for Amarantus' lead asset Mesencephalic-Astrocyte-derived Neurotrophic Factor. Amarantus BioScience is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF.
Csrnewsdaily.com has a finger on the pulse of many sectors including renewable energy, oil, pharma, mining, finance, and healthcare. Our in depth research and analysis of NASDAQ, OTCBB, Pink Sheets, and NYSE has yielded considerable gains for our subscribers.
Our to-the-minute reports and alerts coupled with breaking news, analysis, investment strategies, and FREE subscription email services contribute to our role as one of the leading investor relations marketing firms.
The assembled information disseminated by Csrnewsdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Csrnewsdaily.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Pacific Dynasty Consultants Inc.
2637 E Atlantic Blvd #22611 Pompano Beach, FL 33062